FAILED TRIAL: Ph 3 KEYLYNK-006 trial of KEYTRUDA + maintenance LYNPARZA did not meet dual primary endpoints of OS and PFS in 1L EGFR/ALK/ROS1 WT patients with metastatic nonsquamous NSCLC March 26, 2024
FDA accepts the NDA for ensartinib for the treatment of adult patients with metastatic ALK-positive NSCLC March 19, 2024
Biotheus Expanded Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific ADCs March 18, 2024
Taiho Pharma Enters Exclusive License Agreement with Haihe Biopharma for Gumarontinib (SCC244), an Agent for NSCLC March 12, 2024
China’s NMPA Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer March 12, 2024
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous NSCLC or HR+, HER2 Negative Breast Cancer March 12, 2024
RYBREVANT® (amivantamab-vmjw) + Chemo gets FDA approval for First-line Treatment of Patients With NSCLC with EGFR Exon 20 Insertion Mutations March 12, 2024
Vudalimab monotherapy generally well tolerated with encouraging clinical benefit for heavily-pretreated patients with high-risk metastatic CRPC March 5, 2024
U.S. FDA Breakthrough Therapy Designation for BAY 2927088 for NSCLC Harboring HER2 Activating Mutations March 5, 2024
Abingworth Announces a Strategic Development Financing Agreement with Gilead Sciences; Establishes Joint Steering Committee March 4, 2024
Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer February 26, 2024
Tagrisso demonstrated efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Ph 3 trial February 26, 2024
EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma February 26, 2024
Type II Extension of Indication Application to the EMA Seeking Approval of RYBREVANT + Lazertinib, for 1L Treatment of Patients with EGFR-Mutated NSCLC February 26, 2024
U.S. and EU Regulatory Filings for Neoadjuvant Opdivo and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable NSCLC accepted February 26, 2024
